Alexander Fudukidis | IR |
Spiro Rombotis | President and CEO |
Paul McBarron | EVP, Finance and Chief Operating Officer |
Judy Chiao | VP of Clinical Development and Regulatory Affairs |
Good afternoon, and welcome to the Cyclacel Pharmaceuticals' First Quarter 2018 Results Conference Call and Webcast. Today's call is being recorded. [Operator Instructions] The company will be accepting a limited number of questions submitted via e-mail to the address ir@cyclacel.com. It is now my pleasure to turn the floor over to the company.
Good afternoon, everyone, and thank you for joining the conference call to discuss Cyclacel's first quarter results and business highlights for the quarter ended March 31, 2018.